ECM Biomaterials Foundry Platform

Trylle Biologics is developing an ECM Biomaterials Foundry- a platform for engineering programmable extracellular matrix materials that combine biologically produced ECM components with synthetic polymers, nanomaterials, and electronic interfaces.

The platform is in early development (TRL 1–3), focused on foundational technologies for scalable biomaterials in regenerative medicine, biofabrication, and implantable bioelectronic systems.

A semiconductor foundry does not sell chips — it produces the infrastructure that makes chips possible across many industries. The ECM Biomaterials Foundry works the same way.

One platform. Multiple high-value applications: from neural interfaces that integrate with human tissue to cell therapies that hold up in environments where cold chain logistics fail.

Development Stage

Trylle Biologics operates as a virtual development company. Laboratory infrastructure and pilot manufacturing will be established as the ECM Biomaterials Foundry advances beyond early-stage research.

The founding team has more than three decades of direct experience in cell culture systems, tissue engineering, collagen processing, and biopolymer medical device manufacturing. That experience is the basis for the platform design- not a proxy for it.

Relevant Scientific Domains

Tissue Engineering
Biomaterials Science
Synthetic Biology
Bioelectronics
Biofabrication

The Foundry Concept

Design – Build – Test – Learn

The ECM Biomaterials Foundry applies engineering principles from synthetic biology to extracellular matrix-based materials. Where biofoundries in the synthetic biology field engineer living cells and genetic systems, the Trylle platform is built to engineer the structural biological materials those systems produce — and to integrate them with synthetic polymers, nanomaterials including graphene, and electronic components.

Post-funding, the platform will run on a Design–Build–Test–Learn cycle: formulation design informed by multi-omics data, iterative biophysical characterization, functional validation across application domains, and systematic material refinement. Patents have been filed. Designs are underway.

Platform Outputs Under Development

Engineered ECM biomaterials with tunable rheological and mechanical properties
Hybrid ECM–polymer composites with enhanced thermal stability
ECM-based biofabrication substrates for organoid and tissue printing
Implantable biomaterial interfaces for neural and bioelectronic integration
Biological–electronic integration platforms incorporating nanomaterial architectures

Platform Overview

The core platform combines human atelopeptide collagen from cultured fibroblasts with CMC-polymer systems to produce materials with precisely tunable rheological properties, thermal stability up to and including autoclave conditions, and clinically relevant biocompatibility. The same process supports functionalization with other human ECM proteins and incorporation of biological actives- antibodies, growth factors, cytokines. Core innovations are protected by US Provisional patents.

The decision to use human-derived collagen rather than animal-sourced alternatives is foundational. It produces tissue integration that synthetic materials cannot match, removes cross-species immunogenicity from the equation, and opens clinical translation pathways that animal-derived biomaterials face structural barriers to entering.

The platform is built to work directly with established CDMO partners operating GMP-grade bioreactor systems for scalable human collagen production. This approach allows rapid scale-up without the capital requirements of proprietary infrastructure, while keeping regulatory compliance and government contracting readiness in place from the start.

CDMO Capabilities

Bioreactor systems configured for human cell culture
Scalable production from research to commercial volumes
GMP-compliant facilities with validated processes
Integrated quality control and release testing
Full regulatory documentation support

Every Trylle application — from neural interfaces to behavioral health devices — draws on this shared GMP manufacturing foundation. That shared base compresses development timelines and reduces regulatory risk across the pipeline.

TBI & Neocortical Repair

Structured Cortical Reconstruction Using Human ECM Technology

Focal neocortical injury from stroke, trauma, or neurodegeneration produces permanent functional loss. Adult cortex does not carry the developmental framework needed for organized structural reconstruction — and no current therapy restores it.

Our approach uses structurally engineered neocortical precursor tissue defined by multi-omics mapping and controlled ECM architecture, not cellular differentiation alone. The goal is to provide the physical scaffold that cortical repair requires and currently lacks.

Technical Approach

iPSC-derived neural and mesenchymal progenitors
Embedded in tunable human collagen-CMC backbone
ECM composition matched to developmental tissue
Engineered for laminar cytoarchitecture restoration

Brain-Machine Interface (BMI)

Conventional neural interfaces fail over time because the body treats them as foreign objects. Encapsulation, inflammatory response, and signal degradation are not edge cases — they are the expected outcome with synthetic polyimide substrates.

Our neural interface work uses the platform's thermal stability and biocompatibility to build interfaces that the body does not reject. Human ECM materials integrate with neural tissue in ways synthetic substrates cannot. That difference is what makes long-term stability achievable rather than theoretical.

Key Advantages

True tissue integration rather than encapsulation tolerance
Reduced chronic immune response
Extended operational lifespan
Defense-grade reliability requirements met by material properties, not coatings

The target: a fully biological BMI with tissue-like channel density. An all-natural neural interface for ultra-high-density arrays.

Manufacturing an All Natural Neural Interface for Ultra High Density Arrays

Our goal is a biological BMI with tissue-like channel density

Ambient Biostasis Platform for Cell Therapy Storage and Delivery

Cell Therapies Without the Cold Chain

Cell therapies represent some of the most promising advances in regenerative medicine — and some of the most fragile. Conventional products require continuous cold chain management, specialized handling, and administration within hours of preparation. Those constraints make them effectively unreachable in forward operating environments, austere clinical settings, disaster response scenarios, and long-duration space missions where refrigeration cannot be guaranteed.

Trylle's Ambient Biostasis Platform addresses the cold chain problem at the materials level. Our tunable human collagen ECM system provides a protective biomatrix that maintains cell viability at ambient temperatures — 20–25°C — for extended periods without cryogenic infrastructure. This is not a packaging improvement. It is a different approach to how cell therapies are stored, transported, and delivered.

The platform uses a dual-chamber cartridge architecture that keeps the biomaterial matrix and the therapeutic cell population separated until the moment of administration — preserving viability while enabling field-compatible deployment. No specialized training. No cold storage logistics. No time-critical administration window.

Primary development targets include neural progenitor therapies for TBI treatment in forward operating environments, cell-based wound repair for austere settings, and biologics delivery for extended missions beyond reliable supply chains. The same platform addresses civilian settings where cold chain failure remains a barrier to equitable access to advanced cell therapies.

ANCHOR Qualification Infrastructure

Adaptive Native Collagen Hydrogel for Organ Readiness

The applications above- from neural interfaces to ambient biostasis, all depend on a consistent, translation-ready supply of human biomaterial inputs. ANCHOR is the qualification infrastructure that makes that supply chain defensible at scale.

Developed as a qualification framework for advanced bioprinting applications, ANCHOR gives research and development teams a path to move from animal-derived collagen to human ECM inputs without rebuilding their validation processes. Standardized qualification protocols, material characterization benchmarks, and GMP-compatible processing pathways address the bottleneck that has kept human collagen out of next-generation biomedical applications.

Trylle's current ANCHOR focus is liver tissue bioprinting- building human ECM qualification infrastructure compatible with embedded bioprinting platforms under ARPA-H's bioprinting initiative. The 18-month work plan generates qualification data that benefits Trylle's own pipeline and the broader field of human biomaterial translation.

ANCHOR is not a product. It is what makes Trylle's products possible at clinical and commercial scale, and what positions the platform to meet the manufacturing readiness requirements that government program milestones require.

A 510(k) FDA Approval Pathway:

Prostate Cancer Hydrogel Spacer

510(k) Pathway · Platform Validation · $250M+ Market

Prostate cancer is the most commonly diagnosed cancer in the VA system- roughly 30% of all new cases, with approximately 15,000 new diagnoses and over 200,000 survivors in active treatment annually. Veterans are diagnosed at twice the rate of the general population.

Radiation is a primary treatment modality, but the rectum's proximity to the prostate means side effects that can be nearly as debilitating as the disease. Our injectable hydrogel spacer physically separates the two structures during treatment, reducing rectal radiation dose and the toxicity that follows.

The device is well-tolerated, resorbs without surgical removal, and produces no inflammatory response — properties that follow directly from using human ECM rather than synthetic materials. The 510(k) pathway requires animal studies rather than human clinical trials, which keeps the approval timeline realistic.

The strategic value extends well past the device itself. 510(k) clearance validates our human collagen technology with the FDA, establishes GMP manufacturing credibility, and creates regulatory momentum for more complex applications including neural interfaces and biostasis systems. The prostate spacer market is approximately $250M and growing with prostate cancer incidence.

We are not building products in isolation. We are building the foundry that makes them possible.

Whether you are a researcher, government program manager, investor, or development partner — we are looking for people who understand that the materials problem is the hard problem, and that solving it changes what is possible across every application that depends on it.

CONTACT

info@trylleinc.com · trylleinc.com · Carlsbad, CA